Weekly Insulin Injection Icodec Approved for Type 2 Diabetes Patients in England and Wales

The National Institute for Health and Care Excellence (NICE) has approved a weekly insulin injection, Icodec, for Type 2 diabetes patients in England and Wales. This decision could allow up to 400,000 individuals currently on daily insulin regimens to reduce their injection frequency, marking a notable shift in diabetes management.

Icodec, developed by Novo Nordisk, is administered once a week, contrasting with the standard daily injections of conventional insulin. Clinical trials indicated that Icodec is as effective as daily insulin glargine in controlling blood sugar levels, while also reducing the number of hypoglycaemic episodes – a common and potentially dangerous side effect of insulin therapy.

The move to a less frequent injection schedule is expected to significantly enhance the quality of life for many Type 2 diabetes sufferers. Daily injections can be a considerable burden, impacting daily routines and mental well-being. A weekly alternative offers greater flexibility and convenience, potentially improving treatment adherence.

While NICE has backed Icodec, its availability on the National Health Service (NHS) is subject to negotiations between NHS England and Novo Nordisk on pricing and supply. Should these discussions conclude successfully, the new weekly jab could be rolled out in the coming months, representing a substantial update to diabetes care protocols across the region.